Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance (MGUS)

Laboratory Interpretation

The International Myeloma Society recommends serum protein electrophoresis with M-protein quantification, and free light chain (FLC) assay, which shows an elevated FLC kappa level of 32.02 mg/L and an FLC lambda level of 23.33 mg/L, with a normal FLC ratio of 1.37, in patients with suspected MGUS 1
The patient's serum protein electrophoresis results, including an elevated total protein of 10.6 g/dL and an M-spike of 1.25 g/dL, are consistent with a monoclonal gammopathy 3, 4
The European Society for Medical Oncology recommends measuring serum albumin, which is 3.00 g/dL in this patient, as part of the initial evaluation of MGUS 2

The patient meets the criteria for MGUS, with an M-protein level of 1.25 g/dL, no evidence of end-organ damage, and a normal kappa/lambda ratio, according to the International Myeloma Society 3, 5
The Mayo Clinic risk stratification model places this patient at intermediate risk, with one risk factor present (M-protein >1.0 g/dL) and a normal FLC ratio 3, 6

The National Comprehensive Cancer Network recommends a complete blood count with differential, renal function tests, and calcium and phosphate levels, as well as a bone marrow examination with biopsy, aspirate, and FISH analysis, in patients with MGUS 4, 6
Imaging studies, including a skeletal survey or low-dose whole-body CT, and a DXA scan to assess bone mineral density, are recommended by the International Myeloma Society 4, 5

The European Society for Medical Oncology recommends monitoring intermediate-risk MGUS patients at 6 months initially, and annually thereafter if stable, with careful history and physical examination, serum protein electrophoresis, complete blood count, and creatinine and calcium measurements 3, 6
The International Myeloma Society recommends considering bisphosphonate therapy if bone mineral density testing reveals osteopenia or osteoporosis 5

The Mayo Clinic risk stratification model estimates a 20-year cumulative probability of progression to symptomatic multiple myeloma or related disorders of 21% in this patient, with an annual risk of progression of approximately 1% 3, 6
The International Myeloma Society recommends monitoring for progression risk indicators, including increasing M-protein level, development of abnormal FLC ratio, and evolving iFLC >100 mg/L during follow-up 6, 1

The National Comprehensive Cancer Network recommends avoiding unnecessary repeated bone marrow examinations unless there are signs of disease progression, and instructing patients to report new symptoms promptly, particularly bone pain, fatigue, recurrent infections, or unexplained weight loss 2, 3
The European Society for Medical Oncology recommends being vigilant for development of MGUS-related disorders, such as AL amyloidosis, light chain deposition disease, and peripheral neuropathy 1, 3